NEW YORK (GenomeWeb) – The College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) have issued new guidelines for clinicians using HER2 amplification or mutation testing to inform treatment of advanced gastroesophageal adenocarcinoma, a form of cancer that originates near the junction of the esophagus and stomach.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.